Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A - Asset Resilience Ratio
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (002864) has an Asset Resilience Ratio of -0.13% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shaanxi Panlong Pharmaceutical Group Lim (002864) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Shaanxi Panlong Pharmaceutical Group Lim.
Liquid Assets Composition Over Time
This chart breaks down Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Shaanxi Panlong Pharmaceutical Group Lim for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-2.77 Million | -0.13% |
| Total Liquid Assets | CN¥-2.77 Million | -0.13% |
Asset Resilience Insights
- Limited Liquidity: Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A maintains only -0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A Industry Peers by Asset Resilience Ratio
Compare Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A (2019–2023)
The table below shows the annual Asset Resilience Ratio data for Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.13% | CN¥-2.87 Million ≈ $-419.60K |
CN¥2.13 Billion ≈ $310.96 Million |
+0.47pp |
| 2022-12-31 | -0.61% | CN¥-11.77 Million ≈ $-1.72 Million |
CN¥1.93 Billion ≈ $282.53 Million |
-0.72pp |
| 2021-12-31 | 0.11% | CN¥1.48 Million ≈ $217.12K |
CN¥1.33 Billion ≈ $194.65 Million |
-5.29pp |
| 2019-12-31 | 5.41% | CN¥50.21 Million ≈ $7.35 Million |
CN¥928.88 Million ≈ $135.92 Million |
-- |
About Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd Class A
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd researches and develops, produces, and sells Chinese patent medicines in China. It offers orthopedic, cardiovascular, cerebrovascular, digestive, respiratory, pediatrics, gynecology, hepatobiliary, rheumatism and bone injury, tonic, heat-clearing and detoxifying, and liver and gallbladder drugs, as well as supplements and traditional Chine… Read more